BC Week In Review | Oct 12, 2018
Clinical News

Checkpoint's CK-101 leads to 75% ORR in NSCLC subgroup of Phase I/II

Checkpoint Therapeutics Inc. (NASDAQ:CKPT) said twice-daily 400 mg oral CK-101 (RX518) led to an objective response rate (ORR) of 75% in eight treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) in a dose-expansion...
BC Week In Review | Aug 15, 2016
Clinical News

CK-101: Phase I/II start

Next month, Fortress’ Checkpoint Therapeutics Inc. company will begin an open-label Phase I/II trial of once-daily oral CK-101. The dose-escalation Phase I portion in patients with advanced solid tumors will determine the dose for the...
Items per page:
1 - 2 of 2